Comparative Pharmacology
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus NEOSTIGMINE METHYLSULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDROPHONIUM CHLORIDE versus NEOSTIGMINE METHYLSULFATE.
EDROPHONIUM CHLORIDE vs NEOSTIGMINE METHYLSULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Inhibits acetylcholinesterase at the neuromuscular junction, increasing acetylcholine availability and enhancing cholinergic transmission.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
0.5-2.5 mg intravenously or intramuscularly every 2-4 hours as needed for reversal of neuromuscular blockade or treatment of myasthenia gravis; for reversal of non-depolarizing neuromuscular blockade, 0.03-0.07 mg/kg intravenously with anticholinergic.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 0.7 to 1.2 hours (mean 0.8 h) in healthy adults. In renal impairment, half-life may be prolonged up to 3-4 hours, requiring dose adjustment.
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Renal excretion of unchanged drug accounts for approximately 50% of elimination; the remainder is metabolized by microsomal enzymes and excreted in urine as metabolites. Biliary/fecal elimination is minimal (<5%).
Category C
Category A/B
Cholinesterase Inhibitor
Cholinesterase Inhibitor